Active Biotech AB Interim report January - March 2010

 

·           Laquinimod ― Teva extends its marketing and distribution rights for laquinimod

·           TASQ ― preparations for Phase III trials under way
 

·           ANYARA ― exploratory combination data presented

·           57-57 ― exploratory clinical trial in progress

·           ISI ― project proceeding according to plan

·           RhuDex^(TM) ― preclinical studies in progress

 

·           Net sales of SEK 2.8 M (2.2)

 

·           Operating loss of SEK 51.0 M (loss: 63.7)

 

·           Loss after tax of SEK 53.5 M (loss: 62.2)

 

·           Loss per share for the period amounted to SEK 0.83 (loss: 1.21)

 

·           After the end of the period a directed share issue raised approximately SEK 149 M for the company

 

 

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

 

Göran Forsberg                                   

VP Investor Relations & Business Development                          

Tel: +46 (0)46-19 11 54                                        

 

Hans Kolam                                                                         

CFO                                                                       

Tel: +46 (0)46-19 20 44                                                        

 

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 (0)46-19 20 00

Fax: +46 (0)46-19 11 00

 

This report is also available at www.activebiotech.com